Skip to Main Content

Paper Details

Discovery and systematic assessment of early biomarkers that predict progression to severe COVID-19 disease.
Commun Med (Lond)
4
2023
A9, COVID-19, COVID-19 disease, ERBB2, FINC, IFNL1, S100A8, SARS-, SARS-CoV-2, SARS-CoV-2 infection, TSP1, antibody microarrays, blood, patient, patients, people, plasma
Author NameAffiliation
Anahita Fathi KazerooniUniversity Medical Center Hamburg-Eppendorf, Institute for Infection Research and Vaccine Development (IIRVD)
Anahita Fathi KazerooniBernhard-Nocht-Institute for Tropical Medicine, Department for Clinical Immunology of Infectious Diseases
Anahita Fathi KazerooniGerman Center for Infection Research
Anahita Fathi KazerooniUniversity Medical Center Hamburg-Eppendorf
Anahita Fathi KazerooniUniversity Medical Center Hamburg-Eppendorf, Institute for Infection Research and Vaccine Development (IIRVD)
Anahita Fathi KazerooniBernhard-Nocht-Institute for Tropical Medicine, Department for Clinical Immunology of Infectious Diseases
Anahita Fathi KazerooniGerman Center for Infection Research
Anahita Fathi KazerooniUniversity Medical Center Hamburg-Eppendorf
Marylyn M AddoUniversity Medical Center Hamburg-Eppendorf, Institute for Infection Research and Vaccine Development (IIRVD)
Marylyn M AddoBernhard-Nocht-Institute for Tropical Medicine, Department for Clinical Immunology of Infectious Diseases
Marylyn M AddoGerman Center for Infection Research
  • 1 - 11

Datasets

Release 1.2